Caprius, Inc. Announces 46% 2006 Revenue Growth and New Business Developments.

HACKENSACK, N.J. -- Caprius, Inc. (OTCBB: CAPS) announced revenue for the year ended September 30, 2006 totaled $1,235,469 compared to $848,802 last year, an increase of approximately 46%. Revenue for the fourth quarter ended September 30, 2006 was $401,967, a 25% sequential increase compared to the third quarter ended June 30, 2006. This increase continues the Company's sequential quarterly revenue growth of 13% and 18% for the second and third quarters of 2006, respectively.

Dwight Morgan, President & CEO of Caprius, commented, "Fiscal 2006 was a pivotal year for Caprius. During the year we transitioned to a sales focused organization committed to realizing the market opportunity for our SteriMed Systems. This was evidenced by the strong fourth quarter."

Commenting on Fiscal 2007, Mr. Morgan continued, "As we head into Fiscal 2007, we have before us many opportunities to significantly expand the market penetration of our SteriMed Systems. We are presently in the process of deploying our SteriMed Systems to several dialysis clients, including two that are the leaders in the field both domestically and overseas. One has already received initial shipments and we are on track to ship units to the second dialysis group in early 2007. These customers, with multiple locations both here and abroad, represent a huge opportunity for us in this critical market niche."

In Fiscal 2006, we shipped two SteriMed Juniors to the United States Department of Defense for use by the U.S. Navy. The program for the Navy represents a significant opportunity for us in that the Navy is actively seeking a 'total fleet solution' to medical waste management problems. The Navy had identified 21 potential alternative technology solution providers for medical waste treatment. Our SteriMed Junior was identified as a solution that achieved the Navy's cost, ship impact, and performance metrics. The first unit was for laboratory test and evaluation as part of the U.S. Navy's Shipboard Medical Waste Management Program and the second unit is scheduled for shipboard evaluation in early 2007.

These results are as reported in our recently filed Form 10-KSB.

About Caprius

Caprius, Inc. is a manufacturer of proprietary equipment for the on-site disinfection and disposal of infectious medical waste through its subsidiary, M.C.M. Environmental Technologies, Inc. The Company's innovative SteriMed technology simultaneously shreds and disinfects solid and liquid regulated medical waste, reducing the volume by up to 90% and rendering it harmless for disposal as ordinary waste. The SteriMed units are economical, compact, efficient and convenient, as well as environmentally friendly. The MCM patented technology offers an alternative to hauling and incinerating medical waste. Industry analysts estimate the medical waste market to be approximately $3 billion in the US and approximately $10 billion worldwide. More information on the Company and MCM can be found at www.caprius.com and www.mcmetech.com

Safe Harbor Statement

This press release may contain forward-looking statements that involve risks and uncertainties. These statements refer to future plans, objectives, expectations and intentions. These statements may be identified by the use of words such as "anticipate," "believe," "intend," "plan," "expect" and other similar expressions. The Company's actual results could differ materially from those discussed in, or implied by, such forward-looking statements. You should also be aware of risks and uncertainties that, in the Company's view, could cause actual results to differ materially including changes related to regulatory and environmental approvals, manufacturing, operations, capital needs, technological advances by competitors and changes in health care reform, including reimbursement programs.

Certain information concerning economic trends and performance is based upon or derived from information provided by third-party consultants and other industry sources. While the Company believes that such information is accurate and that the sources from which it was obtained are reliable, it cannot guarantee the accuracy of such information, as it has not independently verified the assumptions on which projections of future trends and performance are based.